Business
Notice of AGM and Annual Report & Accounts
Notice of AGM and Annual Report & Accounts.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 8386W Sareum Holdings PLC 20 November 2017 \n\n\n\n\n\n(AIM: SAR)\n\n\n20 November 2017\n\n\n\n\n \nSareum Holdings plc\n(\"Sareum\" or \"the Company\")\nNotice of AGM and Annual Report & Accounts\nSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, has notified its shareholders that its Annual General Meeting (\"AGM\") will take place at 10.00 a.m. on 14 December 2017 at the offices of Citigate Dewe Rogerson, 3 London Wall Buildings, London Wall, London EC2M 5SY. \nOn 17 November 2017, the Company Annual Report and Accounts for the year ended 30 June 2017 was posted to shareholders who requested a hard copy and the notice convening the 2017 AGM was posted to all shareholders. A copy of both documents has been placed on the Company website.\nFor further information, please contact: \n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / James Sinclair-Ford\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nCitigate Dewe Rogerson (Media enquiries)\n\n\n \n\n\n\n\nShabnam Bashir/ Mark Swallow/ David Dible\n\n\n\n020 7282 9571\n\n\n\n\nNotes for editors: \nSareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\nIts most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.\nSareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.\nThe Company's drug discovery technology plat...